221 related articles for article (PubMed ID: 11901209)
1. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
Lazo JS; Nemoto K; Pestell KE; Cooley K; Southwick EC; Mitchell DA; Furey W; Gussio R; Zaharevitz DW; Joo B; Wipf P
Mol Pharmacol; 2002 Apr; 61(4):720-8. PubMed ID: 11901209
[TBL] [Abstract][Full Text] [Related]
2. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.
Brisson M; Nguyen T; Vogt A; Yalowich J; Giorgianni A; Tobi D; Bahar I; Stephenson CR; Wipf P; Lazo JS
Mol Pharmacol; 2004 Oct; 66(4):824-33. PubMed ID: 15231869
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity.
Brun MP; Braud E; Angotti D; Mondésert O; Quaranta M; Montes M; Miteva M; Gresh N; Ducommun B; Garbay C
Bioorg Med Chem; 2005 Aug; 13(16):4871-9. PubMed ID: 15921913
[TBL] [Abstract][Full Text] [Related]
4. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
Lazo JS; Aslan DC; Southwick EC; Cooley KA; Ducruet AP; Joo B; Vogt A; Wipf P
J Med Chem; 2001 Nov; 44(24):4042-9. PubMed ID: 11708908
[TBL] [Abstract][Full Text] [Related]
5. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
Schepetkin IA; Karpenko AS; Khlebnikov AI; Shibinska MO; Levandovskiy IA; Kirpotina LN; Danilenko NV; Quinn MT
Eur J Med Chem; 2019 Dec; 183():111719. PubMed ID: 31563013
[TBL] [Abstract][Full Text] [Related]
7. Naphthoquinone analogs as inactivators of cdc25 phosphatase.
Ham SW; Park J; Lee SJ; Kim W; Kang K; Choi KH
Bioorg Med Chem Lett; 1998 Sep; 8(18):2507-10. PubMed ID: 9873570
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of a tetronic acid library focused on inhibitors of tyrosine and dual-specificity protein phosphatases and its evaluation regarding VHR and cdc25B inhibition.
Sodeoka M; Sampe R; Kojima S; Baba Y; Usui T; Ueda K; Osada H
J Med Chem; 2001 Sep; 44(20):3216-22. PubMed ID: 11563920
[TBL] [Abstract][Full Text] [Related]
9. Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione.
Pu L; Amoscato AA; Bier ME; Lazo JS
J Biol Chem; 2002 Dec; 277(49):46877-85. PubMed ID: 12356752
[TBL] [Abstract][Full Text] [Related]
10. Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.
Johnston PA; Foster CA; Tierno MB; Shun TY; Shinde SN; Paquette WD; Brummond KM; Wipf P; Lazo JS
Assay Drug Dev Technol; 2009 Jun; 7(3):250-65. PubMed ID: 19530895
[TBL] [Abstract][Full Text] [Related]
11. Fluorinated NSC as a Cdc25 inhibitor.
Park H; Carr BI; Li M; Ham SW
Bioorg Med Chem Lett; 2007 Apr; 17(8):2351-4. PubMed ID: 17379514
[TBL] [Abstract][Full Text] [Related]
12. Synthetic small molecule Cdc25 phosphatases inhibitors.
Garuti L; Roberti M; Pizzirani D
Curr Med Chem; 2008; 15(6):573-80. PubMed ID: 18336271
[TBL] [Abstract][Full Text] [Related]
13. Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties.
Peyregne VP; Kar S; Ham SW; Wang M; Wang Z; Carr BI
Mol Cancer Ther; 2005 Apr; 4(4):595-602. PubMed ID: 15827333
[TBL] [Abstract][Full Text] [Related]
14. Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor.
Tamura K; Rice RL; Wipf P; Lazo JS
Oncogene; 1999 Nov; 18(50):6989-96. PubMed ID: 10597298
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression.
Kabakci Z; Käppeli S; Cantù C; Jensen LD; König C; Toggweiler J; Gentili C; Ribaudo G; Zagotto G; Basler K; Pinna LA; Cozza G; Ferrari S
Sci Rep; 2019 Feb; 9(1):1335. PubMed ID: 30718768
[TBL] [Abstract][Full Text] [Related]
16. Biological evaluation of newly synthesized quinoline-5,8-quinones as Cdc25B inhibitors.
Cossy J; Belotti D; Brisson M; Skoko JJ; Wipf P; Lazo JS
Bioorg Med Chem; 2006 Sep; 14(18):6283-7. PubMed ID: 16782352
[TBL] [Abstract][Full Text] [Related]
17. EK-6136 (3-methyl-4-(O-methyl-oximino)-1-phenylpyrazolin-5-one): a novel Cdc25B inhibitor with antiproliferative activity.
Kim KR; Kwon JL; Kim JS; No Z; Kim HR; Cheon HG
Eur J Pharmacol; 2005 Dec; 528(1-3):37-42. PubMed ID: 16324698
[TBL] [Abstract][Full Text] [Related]
18. Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening.
Lavecchia A; Di Giovanni C; Pesapane A; Montuori N; Ragno P; Martucci NM; Masullo M; De Vendittis E; Novellino E
J Med Chem; 2012 May; 55(9):4142-58. PubMed ID: 22524450
[TBL] [Abstract][Full Text] [Related]
19. Identification of new Cdc25 dual specificity phosphatase inhibitors in a targeted small molecule array.
Ducruet AP; Rice RL; Tamura K; Yokokawa F; Yokokawa S; Wipf P; Lazo JS
Bioorg Med Chem; 2000 Jun; 8(6):1451-66. PubMed ID: 10896122
[TBL] [Abstract][Full Text] [Related]
20. A novel synthetic inhibitor of CDC25 phosphatases: BN82002.
Brezak MC; Quaranta M; Mondésert O; Galcera MO; Lavergne O; Alby F; Cazales M; Baldin V; Thurieau C; Harnett J; Lanco C; Kasprzyk PG; Prevost GP; Ducommun B
Cancer Res; 2004 May; 64(9):3320-5. PubMed ID: 15126376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
